

# Teresa Lozano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1015894/publications.pdf>

Version: 2024-02-01

21  
papers

602  
citations

758635

12  
h-index

752256

20  
g-index

21  
all docs

21  
docs citations

21  
times ranked

1144  
citing authors

#	ARTICLE	IF	CITATIONS
1	TCR-induced FOXP3 expression by CD8+ T cells impairs their anti-tumor activity. <i>Cancer Letters</i> , 2022, 528, 45-58.	3.2	7
2	Overcoming T cell dysfunction in acidic pH to enhance adoptive T cell transfer immunotherapy. <i>Oncolmmunology</i> , 2022, 11, 2070337.	2.1	9
3	Intratumoral STING Agonist Injection Combined with Irreversible Electroporation Delays Tumor Growth in a Model of Hepatocarcinoma. <i>BioMed Research International</i> , 2021, 2021, 1-9.	0.9	8
4	Searching for Peptide Inhibitors of T Regulatory Cell Activity by Targeting Specific Domains of FOXP3 Transcription Factor. <i>Biomedicines</i> , 2021, 9, 197.	1.4	3
5	SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation. , 2021, 9, e001496.		42
6	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. <i>Journal of Nanobiotechnology</i> , 2021, 19, 102.	4.2	27
7	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity. <i>Molecular Therapy</i> , 2019, 27, 1878-1891.	3.7	38
8	FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells. <i>Anticancer Research</i> , 2019, 39, 5369-5374.	0.5	5
9	Therapeutic Effect of Irreversible Electroporation in Combination with Poly-ICLC Adjuvant in Preclinical Models of Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2019, 30, 1098-1105.	0.2	15
10	Genetic Modification of CD8+ T Cells to Express EGFR: Potential Application for Adoptive T Cell Therapies. <i>Frontiers in Immunology</i> , 2019, 10, 2990.	2.2	14
11	The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer. <i>Oncolmmunology</i> , 2018, 7, e1409321.	2.1	15
12	Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms. <i>Haematologica</i> , 2018, 103, 1065-1072.	1.7	10
13	Immunomodulatory Properties of Carvone Inhalation and Its Effects on Contextual Fear Memory in Mice. <i>Frontiers in Immunology</i> , 2018, 9, 68.	2.2	14
14	Expansion of Tumor-Infiltrating CD8+ T cells Expressing PD-1 Improves the Efficacy of Adoptive T-cell Therapy. <i>Cancer Research</i> , 2017, 77, 3672-3684.	0.4	99
15	Relevance of CD6-Mediated Interactions in the Regulation of Peripheral T-Cell Responses and Tolerance. <i>Frontiers in Immunology</i> , 2017, 8, 594.	2.2	12
16	Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor. <i>Oncotarget</i> , 2017, 8, 71709-71724.	0.8	27
17	Targeting inhibition of Foxp3 by a CD28 2â€²-Fluro oligonucleotide aptamer conjugated to P60-peptide enhances active cancer immunotherapy. <i>Biomaterials</i> , 2016, 91, 73-80.	5.7	43
18	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <i>Oncotarget</i> , 2015, 6, 27160-27175.	0.8	51

#	ARTICLE	IF	CITATIONS
19	Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation. Journal of Immunology, 2015, 195, 3180-3189.	0.4	44
20	Searching for the Achilles Heel of FOXP3. Frontiers in Oncology, 2013, 3, 294.	1.3	22
21	A Peptide Inhibitor of FOXP3 Impairs Regulatory T Cell Activity and Improves Vaccine Efficacy in Mice. Journal of Immunology, 2010, 185, 5150-5159.	0.4	97